CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trendsDublin, Dec. 09, ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...

As of Nov. 11, shares of CRISPR Therapeutics AG were priced at $55.21, up 0.64% over the past year, underperforming the S&P 500 by 7.2 percentage points. CRISPR develops gene-based medicines utilizing ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...